More about

Bleeding

News
October 20, 2020
1 min read
Save

ISAR PLASTER

ISAR PLASTER

A glycoprotein VI inhibitor (Revacept, AdvanceCor) as alternative platelet inhibition strategy during PCI for CAD.

News
October 20, 2020
1 min read
Save

ELDERCARE-AF

ELDERCARE-AF

Low-dose edoxaban (Savaysa, Daiichi Sankyo) vs. placebo for prevention of stroke and systemic embolism in patients aged at least 80 years with AF.

News
October 17, 2020
2 min read
Save

14-day DAPT with nanocoated stent inferior to standard short-term DAPT strategy

14-day DAPT with nanocoated stent inferior to standard short-term DAPT strategy

Among patients on oral anticoagulation, those who had dual antiplatelet therapy for 14 days after PCI with a nanocoated stent had worse outcomes compared with those assigned 3-to-6-month DAPT after PCI with a drug-eluting stent.

News
October 15, 2020
5 min read
Save

Shorter DAPT post-PCI noninferior to longer duration in high bleeding risk

Shorter DAPT post-PCI noninferior to longer duration in high bleeding risk

Dual antiplatelet therapy for 1 month or 3 months was noninferior to a 12-month duration with regard to all-cause mortality and MI in patients with high bleeding risk undergoing PCI, researchers found.

News
October 14, 2020
3 min read
Save

Ticagrelor monotherapy reduces bleeding, does not impact ischemia after PCI for STEMI

Ticagrelor monotherapy reduces bleeding, does not impact ischemia after PCI for STEMI

Among patients with STEMI who underwent PCI with an ultrathin bioresorbable polymer sirolimus-eluting stent, switching to ticagrelor monotherapy after 3 months reduced bleeding risk, according to the TICO-STEMI trial.

News
October 01, 2020
1 min read
Save

FDA expands indication for DES to include patients with high bleeding risk

FDA expands indication for DES to include patients with high bleeding risk

Medtronic announced that the FDA approved an expanded indication for a drug-eluting stent to include patients with high bleeding risk who take dual antiplatelet therapy for 1 month after PCI.

News
October 01, 2020
3 min read
Save

$1.7 million NIH grant to fund research on rare genetic bleeding disorder

$1.7 million NIH grant to fund research on rare genetic bleeding disorder

The NIH has awarded a $1.7 million grant to fund research into potential treatments for hereditary hemorrhagic telangiectasia, a frequently misdiagnosed but potentially life-threatening bleeding disorder.

News
September 22, 2020
4 min read
Save

Rapid bedside genetic testing enhances safety, efficacy of antiplatelet therapy

Rapid bedside genetic testing enhances safety, efficacy of antiplatelet therapy

The landmark TAILOR-PCI trial showed encouraging evidence for genotype-guided antiplatelet therapy.

News
September 08, 2020
2 min read
Save

Ticagrelor may confer risk for death, bleeding in older patients with ACS vs. clopidogrel

Ticagrelor may confer risk for death, bleeding in older patients with ACS vs. clopidogrel

Among patients 80 years or older, treatment of ACS with ticagrelor was associated with greater risk for death and bleeding compared with clopidogrel, researchers reported.

News
September 04, 2020
4 min read
Save

Novel GPVI inhibitor may lower bleeding risk during PCI for CAD

Novel GPVI inhibitor may lower bleeding risk during PCI for CAD

A higher dose of a glycoprotein VI inhibitor in patients with CAD who underwent PCI resulted in more pronounced platelet inhibition without increasing bleeding risk, researchers found in the ISAR PLASTER trial.

View more